Navigation Links
"O-Shot™" May Improve Female Sexual Response
Date:1/17/2012

minimal discomfort. But because it has not been yet been studied in a comprehensive way, all women should undergo this procedure only as part of a clinical research trial." noted Dr. Wood.

"We recognize that this data is preliminary and must be confirmed by rigorous scientific research before making it widely available to patients. We are now initiating a multicenter clinical trial to definitively examine the effectiveness of this procedure. We are currently adding additional collaborating physicians to the study and are open to considering other candidates. Acceptance criteria include having an excellent understanding of female anatomy, being highly skilled at performing precise medical procedures and having an outstanding reputation among their peers," said Dr. Benito Villanueva, Medical Director at La Jolla Centre for Sexual Health and O-Shot™ Director of Physician Training.

The O-Shot is one of several procedures that involve using platelet-derived growth factors to non-invasively treat common medical problems. The first such procedure was the "Vampire Facelift," which has been featured in numerous diverse media outlets including the New York Times, and the television shows "Dr. Oz" and "The Doctors."

Samuel Wood, M.A., M.D., Ph.D., M.B.A. is a renowned reproductive endocrinologist and stem cell scientist. He is the medical director of Reproductive Sciences Center and the Scientific Director at La Jolla Centre for Sexual Health. He has been featured in numerous print and broadcast media stories and is a listee in Marquis "Who's Who in America" and "Who's Who in the World."

Charles Runels, M.D. is a cosmetic physician, best-selling author and the inventor of several PDGF-based therapies including the "Vampire Facelift."

Benito Villanueva, M.D., has been practicing medicine for over 20 years and has developed a sterling reputation in the field of sexual health a
'/>"/>

SOURCE Samuel Wood, M.D.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Self-assembling polymer arrays improve data storage potential
2. Beaumont Doctors Invention Improves Cataract Surgery Outcomes
3. Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions
4. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
5. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
6. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Global Psychiatrists Unite to Improve Services in Mental Health
9. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
10. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
11. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HONG KONG , July 31, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... with the U.S. Securities and Exchange Commission. The filed ... year ended March 31, 2015. The Form 20-F can ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... on new patient data supporting the Ross heart, reconstruction procedure ... ... procedure, ATLANTA, Oct. 7 CryoLife, Inc. (NYSE: CRY ... surgeons from around the globe will participate in the,Ross Summit 2008, ...
... AMERIGROUP,Corporation (NYSE: AGP ) today announced ... quarter ended September 30, 2008, after the market ... Eastern Time on Thursday, October,23, 2008, AMERIGROUP,s management ... earnings and other information., To listen to ...
... to Save Millions of Lives, GERMANTOWN, Md., ... company focused on development of medical,countermeasures for biodefense ... a multiyear contract for advanced development of a,vaccine ... the National,Institute of Allergy and Infectious Diseases (NIAID), ...
Cached Biology Technology:CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 3
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... URBANA A new strategy to manage invasive species ... the Grand River Grasslands, an area within the North ... along with his colleagues at Iowa State and Oklahoma ... effort to establish a more diverse landscape for native ...
... 9, 2012More than half (52%) of the companies comprising ... revenue-generating, compared to about 21% four years ago, reports ... those companies, 31% have commercial products and 21% are ... to the current issue of GEN . ...
... July 11, and join a public forum with North ... Environmental Protection Agency Administrator Lisa P. Jackson, Canadian Environment ... Quesada. The webcast will kick off at 9 ... July 9 and 10 Joint Public Advisory Committee workshop ...
Cached Biology News:Grassroots approach to conservation developed 2Grassroots approach to conservation developed 3GEN reports on growth of tissue engineering revenues 2
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... ZMD.414. Immunogen: Synthetic peptide derived from ... rat mTOR (Mammalian target of rapamycin FRAP ... human mTOR protein. On Western blots ... kDa. Reactivity: Human (positive control: HEK293 ...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
...
Biology Products: